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Pathogenic mycobacteria trigger formation of organized granu-
lomas. As granulomas mature, they induce angiogenesis and
vascular permeability. Here, in a striking parallel to tumor
pro-angiogenic signaling, we identify angiopoietin-2 (ANG-2)
induction as an important component of vascular dysfunction
during mycobacterial infection. Mycobacterial infection in
humans and zebrafish results in robust induction of ANG-2 ex-
pression from macrophages and stromal cells. Using a small-
molecule inhibitor closely related to one currently in clinical
trials, we link ANG-2/TIE2 signaling to vascular permeability
during mycobacterial infection. Targeting granuloma-induced
vascular permeability via vascular endothelial-protein tyrosine
phosphatase inhibition limits mycobacterial growth, suggesting
a new strategy for host-directed therapies against tuberculosis.
Keywords. Mycobacterium tuberculosis; granuloma;
vascular permeability; angiopoietin; TIE2; VE-PTP; zebrafish.
Granulomas lie at the epicenter of tuberculosis biology. Pathol-
ogy studies have identified key structural and immunological
changes that occur during disease [1]. As granulomas mature,
stromal tissue is remodeled, with recruitment of blood vessels
reminiscent of ectopic and dysfunctional vasculature observed
in tumors [2–4].
Vascular dysfunction in mycobacterial infection is character-
ized by two major components. There is ectopic growth of ves-
sels around granulomas, resulting in increased vascular density.
This growth is driven by the vascular endothelial growth factor
(VEGF)–VEGF receptor (VEGFR) signaling axis and serves to
alleviate granuloma hypoxia [3, 4]. Second, increased perme-
ability is noted in the vasculature around granulomas.
VEGFR inhibition also reduces infection-induced vascular per-
meability [3], but the role of vascular permeability in mycobac-
terial pathogenesis has not been examined in isolation.
Angiopoietin-1 (ANG-1) and ANG-2 are key regulators of
endothelial cells via their common receptor, TIE2 [5]. Under
physiological conditions, ANG-1 binds and activates TIE2 to
promote vessel stability and quiescence, thereby limiting angio-
genesis and vascular permeability. In contrast, ANG-2 binds
TIE2 with similar affinity but acts as a context-dependent an-
tagonist. ANG-2 expression is induced under pathological con-
ditions and antagonizes the stabilizing effects of ANG-1/TIE2
signaling to facilitate angiogenesis and vascular remodeling.
In cancer and inflammatory diseases, increased expression of
ANG-2 in combination with an increased level of VEGF leads
to enhanced tumor vascularity but with aberrant vessels that fail
to mature, owing to persistent destabilizing effects of ANG-2
and VEGF. Stabilizing effects of ANG-1/TIE2 are further inhib-
ited by vascular endothelial-protein tyrosine phosphatase
(VE-PTP), which dephosphorylates TIE2, thereby blunting
downstream signaling [6–8].
Here we identify robust ANG-2 expression in and around
human tuberculous granulomas and improved host outcomes
in the zebrafish–Mycobacterium marinum model via down-
stream modulation of this pathway. Using a member of a
newly developed class of small-molecule inhibitors of VE-PTP,
we show that stabilization of TIE2 signaling alleviates infec-
tion-induced vascular permeability independently of neovascula-
rization. The rescue of vascular integrity limits mycobacterial




Analysis of human granuloma samples was approved by the
Duke Medicine Institutional Review Board. Zebrafish experi-
ments were approved by the Duke University Institutional An-
imal Care and Use Committee.
Human Granulomas
We retrospectively ascertained patients who presented to the
Duke University Health System during 2005−2014 and had sur-
gical pathology specimens reported to contain granulomas. By
use of DEDUCE, a Web-based tool that permits access to elec-
tronic clinical data, cases were ascertained by searching for key-
words “granuloma” or “granulomatous” in combination with
International Classification of Disease codes 010–018 (diseases
due to tuberculosis) or 137 (late effects of tuberculosis). Record
review confirmed microbiological confirmation of each case.
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Detection of ANG-2
Five-micrometer sections were deparaffinized and rehydrated.
Antigen retrieval was performed in a pressure cooker in 10
mM Tris/1 mM ethylenediaminetetraacetic acid (pH 9.0) for
10 minutes. Sections were blocked in phosphate-buffered sa-
line/2.5% goat serum for 1 hour, followed by overnight incuba-
tion with either a 1:100 dilution of rabbit anti-ANG-2
(GTX28452; GeneTex) or a 1:100 dilution of rabbit immuno-
globulin G isotype control antibody (10500C; ThermoFisher)
and with a 1:50 dilution of mouse anti-CD68 (clone KP-1;
Dako). Primary antibodies were detected by incubating with
goat anti-rabbit Alexa 568– and goat anti-mouse Alexa 647–
conjugated secondary antibodies, washed, and mounted in
DAPI Fluoromount-G.
Zebrafish Infection Assays
Two days after fertilization, larvae were anesthetized in 160 µg/
mL Tricaine (Sigma Aldrich) and injected via either the caudal
vein or trunk 48 hours after fertilization with approximately 200
M. marinum organisms [3]. Infected larvae were recovered into
water supplemented with 1-phenyl-2-thiourea (Sigma-
Aldrich; final concentration, 45 µg/mL). After 6 days, larvae
were anesthetized with tricaine prior to fixation, imaging, or
analysis by a microangiography assay. For adults, zebrafish
were anesthetized in 120 µg/mL Tricaine (Sigma Aldrich) and
intraperitoneally injected with approximately 400 M. marinum
organisms [3]. Infected adults were maintained at 28°C. After
14 days, adults were euthanized by tricaine overdose for deter-
mination of the number of colony-forming units (CFU).
Drug Treatment
AKB-9785 (Aerpio Therapeutics) was dissolved in dimethyl
sulfoxide and administered to larvae by soaking immediately
after infection at a concentration of 13 µM or to adults after
the first week of infection at a concentration of 50 µM. Drug
was refreshed every 2 days.
Microangiography
Six days after infection, larvae were anesthetized in 160 µg/mL tri-
caine and injected via caudal vein with 10 nL of dextran-Texas Red
70 000 MW (Life Technologies; 1 mg/mL concentration). Injected
larvae were rinsed and immediately mounted in methylcellulose
for fluorescence microscopy 10 minutes after dextran injection.
Vascular leakage was calculated as a ratio of intersomitic dex-
tran–Texas Red signal to aortic dextran–Texas Red signal.
Quantification of Bacterial Burden
Larval infection burden was measured as the number of pixels
above background in ImageJ, using thresholding of single-chan-
nel images and the Analyze Particles function. Infected adult
zebrafish were pretreated with 25 µg/mL hygromycin for
2 hours before harvesting, to reduce microbiota load. Zebrafish
were euthanized by tricaine overdose and homogenized by a
bead mill, using two 10-second bursts. Homogenate was plated
on Middlebrook 7H10 (262 710; Difco) supplemented with
OADC, hygromycin (H0654; Sigma-Aldrich, 50 µg/L), and am-
photericin B (SV3007801; Thermo Scientific, 10 mg/L).
Statistical Analyses
Data are presented as mean ± standard deviation. Experiments
were analyzed with unpaired Student t tests, or Welch’s t test
where appropriate.
RESULTS
ANG-2 Is Expressed in and Around Human Mycobacterial Granulomas
Robust induction of VEGFA in granuloma macrophages has
been previously observed [3, 4]. We used dual immunofluores-
cence to investigate the expression of a parallel pro-angiogenic
molecule ANG-2 by CD68-positive macrophages in tissue from
patients infected withMycobacterium tuberculosis. We observed
strong expression of ANG-2 by granuloma-associated macro-
phages in lung tissue, as well as staining in cells negative for
the CD68 macrophage marker, consistent with both a macro-
phage and stromal source in mycobacterial granulomas
(Figure 1A and 1B and Supplementary Figures 1 and 2). Pre-
sumptive endothelial expression of ANG-2 was observed at a
lower level than in macrophages, and uninvolved regions of
the lung were largely negative for ANG-2.
Ang2 Is Expressed Within M. marinum Granulomas in Zebrafish
The zebrafish–M. marinum infection model is a validated and
tractable natural host-mycobacterial infection system that we
have previously used to model infection-induced angiogenesis,
with central elements of granulomas conserved with humans,
including angiogenesis and vascular leakage [3, 4]. To examine
whether mycobacterial granulomas recapitulate the ANG-2 ex-
pression observed in human granulomas, we performed anti-
body staining in larval granulomas. We identified consistent
Ang2 induction within mycobacterial granulomas (Figure 1C
and 1D and Supplementary Figure 3).
Inhibition of VE-PTP Reduces Infection-Induced Vascular Permeability
TIE2 is a critical regulator of vascular stability. ANG-2 acts di-
rectly as a TIE2 antagonist to limit vascular stability. An impor-
tant downstream regulator of TIE2 signaling is VE-PTP, an
endothelial cell-specific receptor-type protein tyrosine phos-
phatase that physically associates with, dephosphorylates, and
inhibits TIE2 [9]. An extensive structure-based effort to target
this phosphatase resulted in the development of a panel of high-
ly selective pharmacological inhibitors of VE-PTP that bind the
enzyme’s active site with a subnanomolar Ki; treatment of endo-
thelial cells with these compounds results in potent activation of
TIE2 signaling [6]. Inactivation of VE-PTP with these com-
pounds can activate TIE2 even in the presence of high levels
of ANG-2 expression [6, 8]. The lead clinical compound in
this class, AKB-9778, is currently in clinical trials for diabetic
macular edema, a disease characterized by increased vascular
permeability, where it has been well tolerated without safety
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concerns [10, 11], suggesting that these compounds could rap-
idly be translated to treatment of infectious diseases.
Zebrafish have conserved orthologs of ANG-2, TIE2, and
VE-PTP; importantly, the active site and the stabilizing residues
in zebrafish VE-PTP are conserved in humans [6, 12]. Owing to
ongoing clinical trials with AKB-9778, we used AKB-9785, an
inhibitor of VE-PTP that is highly structurally similar to AKB-
9778, to investigate whether activation of TIE2 in the presence
of an elevated ANG-2 level could alter vascular permeability
and/or angiogenesis in the M. marinum model.
Figure 1. Angiopoietin-2 (ANG-2) is expressed around mycobacterial granulomas. A, Detection of ANG-2 expression, pseudo-colored red, in CD68-positive macrophages,
pseudo-colored green, by fluorescent immunodetection in a section of human lung from a patient infected with Mycobacterium tuberculosis. The image is representative of 3
examined patient samples infected with M. tuberculosis. B, Detection of ANG-2 expression from the field of view in panel A. C, Detection of zebrafish Ang2 (magenta) by
antibody staining around Mycobacterium marinum–tomato granulomas in a Tg(kdrl:egfp) embryo where the blood vessels are marked with enhanced green fluorescent protein
expression. D, Detection of zebrafish Ang2 expression from the field of view in panel C. White arrowheads indicate the largest mycobacterial granulomas in each field of view.
Scale bars represent 100 µm.
Figure 2. Activation of TIE2 signaling reduces mycobacterial burden. A, Representative images of ectopic vascularization and vascular leak in Tg(kdrl:egfp) embryos infected with
Mycobacterium marinum–cerulean and injected with dextran–Texas red. Scale bar represents 100 µm. B, Quantification of vascular leak in M. marinum–infected embryos treated
with AKB-9785. C, Quantification of bacterial burden by fluorometry in M. marinum–infected embryos treated with AKB-9785. D, Quantification of the bacterial burden by a colony-
forming units (CFU) recovery assay 2 weeks afterM. marinum infection in adult zebrafish treated with AKB-9785 from 1 week after infection. Error bars represent standard deviations.
Statistical testing was performed by unpaired Student t tests, with 3 independent biological replicates for each panel. Abbreviation: DMSO, dimethyl sulfoxide.
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To assess infection-induced vasculopathies, we injected
M. marinum into the trunk of transgenic Tg(kdrl:egfp)s843 ze-
brafish, where the blood vessels form stereotypical networks
and are marked by green fluorescent protein expression, allow-
ing intravital imaging of infection-induced angiogenesis and
vascular permeability by detecting extravascular fluorescence
following microangiography with high-molecular-weight dex-
tran–Texas Red (Figure 2A and Supplementary Figure 4A) [3].
A previous report demonstrated reduced tumor-induced an-
giogenesis in zebrafish following VE-PTP inhibition with a
relatively high dose of 150 µM AKB-9778 [7]. However, treat-
ment of infected zebrafish with a cell-culture-equivalent dose
of 13 µM AKB-9785 did not affect infection-induced angiogen-
esis, as similar levels of ectopic vasculature were observed in
treated and control groups 6 days after infection (Supplementary
Figure 4B).
However, analysis of the leakage of high-molecular-weight
dextran into the somitic tissue around sites of infection revealed
that treatment with AKB-9785 markedly decreased infection-
induced vascular leakiness even around highly neovascularized
granulomas (Figure 2B).
Inhibition of VE-PTP Limits Mycobacterial Growth
We next quantified the mycobacterial burden in infected
zebrafish larvae to determine whether reduction in vascular per-
meability inhibited mycobacterial growth comparably to the
total inhibition of angiogenesis by VEGFR inhibition [3]. We
found that AKB-9785 treatment reduced the mycobacterial bur-
den in trunk-injected zebrafish embryos by a similar magnitude
to that previously reported for VEGFR inhibition (Figure 2C).
We reasoned that, since AKB-9785 treatment appeared to act
independently of angiogenesis in our model, we would see a sim-
ilar effect on mycobacterial infections established in areas with
dense vascular beds. Therefore, we infected zebrafish embryos
by caudal vein injection withM. marinum, which stereotypically
results in granulomas forming adjacent to existing vascular beds.
We found that AKB-9785 treatment reduced mycobacterial bur-
den in this setting, confirming that the effects on mycobacterial
growth were independent of an antiangiogenic effect (Figure 2C).
We investigated the effectiveness of AKB-9785 treatment in
adult zebrafish infected withM. marinum [3].We treated infected
adults beginning 1 week after infection and found that AKB-9785
treatment reduced themycobacterial burden by approximately 0.5
log10 CFU over 2 weeks of treatment (Figure 2D). Finally, to ex-
clude the possibility that AKB-9785 is acting as an antibiotic
againstM.marinum, we showed that the drug had no effect during
in vitro growth (Supplementary Figure 5).
DISCUSSION
Infection-mediated angiogenesis driven by the VEGF-VEGFR
signaling axis has been previously identified as a tractable target
for host-directed therapy against tuberculosis [3, 4]. However,
long-term administration of VEGF inhibitors has produced un-
acceptable rates of arterial thromboembolic events [13]. This
study complements the approach of broad inhibition of granu-
loma vascularization with a narrower approach of normalizing
the permeability of the granuloma vasculature that may deliver
a better safety profile than long-term administration of VEGFR-
blocking agents. Notably, the related VE-PTP inhibitor, AKB-
9778, has been well tolerated in clinical trials for diabetic macular
edema thus far [10]. In a recent phase IIa study of patients with
diabetic macular edema, it resulted in significant improvements
when combined with anti-VEGF therapy but not as a monother-
apy [11]. Nonetheless, our results support the possibility that tar-
geting vascular permeability through TIE2 activation may
provide an additional therapeutic target in tuberculosis.
The physiologically high density of lung vasculature is an im-
portant consideration in host-directed tuberculosis treatments.
We previously observed decreased vascular leakiness in VEGFR
inhibitor–treated zebrafish larvae, but this did not translate into
better infection control when granulomas formed near dense
vascular beds [3]. Here we found that specific targeting of vas-
cular permeability with AKB-9785 helped to control infection
even around sites with high-density vasculature. Taken togeth-
er, these data suggest that TIE2 activation triggered by VE-PTP
inhibition increases the integrity of both existing and ectopic
vasculature to reduce mycobacterial growth.
Studies using a rodent Mycoplasma pulmonis model have
demonstrated an important role for ANG-2 in destabilizing vas-
culature during Mycoplasma infection [14]. However, in the
Mycoplasma infection model, the permeability changes may
be mediated by changes in the recruitment of pericytes [14], a
cell type only recently defined in zebrafish [15], whereas the ef-
fect of VE-PTP inhibition on vascular leak appears to be pri-
marily through adherens junctions [6]. However, it is possible
that both mechanisms could be involved or that they could be
interrelated.
Overall, this study provides evidence of a pathological role for
the ANG-2/TIE2/VE-PTP signaling axis in mycobacterial in-
fection. Our findings suggest that VE-PTP inhibition and cor-
responding TIE2 stabilization may serve as novel host-directed
therapies for mycobacterial infections.
Supplementary Data
Supplementary materials are available at http://jid.oxfordjournals.org. Con-
sisting of data provided by the author to benefit the reader, the posted ma-
terials are not copyedited and are the sole responsibility of the author, so
questions or comments should be addressed to the author.
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following microangiography with high-molecular-weight dex-
tran–Texas Red (Figure 2A and Supplementary Figure 4A) [3].
A previous report demonstrated reduced tumor-induced an-
giogenesis in zebrafish following VE-PTP inhibition with a
relatively high dose of 150 µM AKB-9778 [7]. However, treat-
ment of infected zebrafish with a cell-culture-equivalent dose
of 13 µM AKB-9785 did not affect infection-induced angiogen-
esis, as similar levels of ectopic vasculature were observed in
treated and control groups 6 days after infection (Supplementary
Figure 4B).
However, analysis of the leakage of high-molecular-weight
dextran into the somitic tissue around sites of infection revealed
that treatment with AKB-9785 markedly decreased infection-
induced vascular leakiness even around highly neovascularized
granulomas (Figure 2B).
Inhibition of VE-PTP Limits Mycobacterial Growth
We next quantified the mycobacterial burden in infected
zebrafish larvae to determine whether reduction in vascular per-
meability inhibited mycobacterial growth comparably to the
total inhibition of angiogenesis by VEGFR inhibition [3]. We
found that AKB-9785 treatment reduced the mycobacterial bur-
den in trunk-injected zebrafish embryos by a similar magnitude
to that previously reported for VEGFR inhibition (Figure 2C).
We reasoned that, since AKB-9785 treatment appeared to act
independently of angiogenesis in our model, we would see a sim-
ilar effect on mycobacterial infections established in areas with
dense vascular beds. Therefore, we infected zebrafish embryos
by caudal vein injection withM. marinum, which stereotypically
results in granulomas forming adjacent to existing vascular beds.
We found that AKB-9785 treatment reduced mycobacterial bur-
den in this setting, confirming that the effects on mycobacterial
growth were independent of an antiangiogenic effect (Figure 2C).
We investigated the effectiveness of AKB-9785 treatment in
adult zebrafish infected withM. marinum [3].We treated infected
adults beginning 1 week after infection and found that AKB-9785
treatment reduced themycobacterial burden by approximately 0.5
log10 CFU over 2 weeks of treatment (Figure 2D). Finally, to ex-
clude the possibility that AKB-9785 is acting as an antibiotic
againstM.marinum, we showed that the drug had no effect during
in vitro growth (Supplementary Figure 5).
DISCUSSION
Infection-mediated angiogenesis driven by the VEGF-VEGFR
signaling axis has been previously identified as a tractable target
for host-directed therapy against tuberculosis [3, 4]. However,
long-term administration of VEGF inhibitors has produced un-
acceptable rates of arterial thromboembolic events [13]. This
study complements the approach of broad inhibition of granu-
loma vascularization with a narrower approach of normalizing
the permeability of the granuloma vasculature that may deliver
a better safety profile than long-term administration of VEGFR-
blocking agents. Notably, the related VE-PTP inhibitor, AKB-
9778, has been well tolerated in clinical trials for diabetic macular
edema thus far [10]. In a recent phase IIa study of patients with
diabetic macular edema, it resulted in significant improvements
when combined with anti-VEGF therapy but not as a monother-
apy [11]. Nonetheless, our results support the possibility that tar-
geting vascular permeability through TIE2 activation may
provide an additional therapeutic target in tuberculosis.
The physiologically high density of lung vasculature is an im-
portant consideration in host-directed tuberculosis treatments.
We previously observed decreased vascular leakiness in VEGFR
inhibitor–treated zebrafish larvae, but this did not translate into
better infection control when granulomas formed near dense
vascular beds [3]. Here we found that specific targeting of vas-
cular permeability with AKB-9785 helped to control infection
even around sites with high-density vasculature. Taken togeth-
er, these data suggest that TIE2 activation triggered by VE-PTP
inhibition increases the integrity of both existing and ectopic
vasculature to reduce mycobacterial growth.
Studies using a rodent Mycoplasma pulmonis model have
demonstrated an important role for ANG-2 in destabilizing vas-
culature during Mycoplasma infection [14]. However, in the
Mycoplasma infection model, the permeability changes may
be mediated by changes in the recruitment of pericytes [14], a
cell type only recently defined in zebrafish [15], whereas the ef-
fect of VE-PTP inhibition on vascular leak appears to be pri-
marily through adherens junctions [6]. However, it is possible
that both mechanisms could be involved or that they could be
interrelated.
Overall, this study provides evidence of a pathological role for
the ANG-2/TIE2/VE-PTP signaling axis in mycobacterial in-
fection. Our findings suggest that VE-PTP inhibition and cor-
responding TIE2 stabilization may serve as novel host-directed
therapies for mycobacterial infections.
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sisting of data provided by the author to benefit the reader, the posted ma-
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questions or comments should be addressed to the author.
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